Andy Hill

Andy Hill is the Chief Executive Officer (CEO) of NuVision Biotherapies Ltd, a biotechnology company focused on developing regenerative therapies for ophthalmology.12

Key points about Andy Hill:

1. He joined NuVision as CEO with over 35 years of experience in the European and US medical device industry.3

2. Andy has both entrepreneurial and hands-on experience in building early-stage businesses that bring new and disruptive technologies to international markets.1

3. His previous experience includes co-founding and launching Intelligent Ultrasound Limited out of the University of Oxford in 2010.13

4. Andy was one of the key leaders in taking PercuSurge Inc. from first-in-man trials to their $225 million trade sale to Medtronic Inc.1

5. Before joining NuVision, he was involved with an AI-based imaging analytics business called Sēon Diagnostics Limited.1

6. At NuVision, Andy is leading the company's plans for international expansion and growth.2

7. He has expressed enthusiasm for NuVision's product Omnigen, describing it as an "exciting, proven product that is already making a real difference, helping patients with complex, hard to heal wounds recover".1

Andy Hill's appointment as CEO of NuVision Biotherapies was announced in January 2022, marking a significant step in the company's growth and development plans.12